148672-74-6

Basic information

• Product Name: ethyl N-(t-butyloxycarbonyl)nipecotate
• CAS NO: 148672-74-6
• Molecular Weight: 257.33
• Mol File: 148672-74-6.mol
• Article Data: 29

Chemical Properties

• CAS DataBase Reference: ethyl N-(t-butyloxycarbonyl)nipecotate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl N-(t-butyloxycarbonyl)nipecotate(148672-74-6)
• EPA Substance Registry System: ethyl N-(t-butyloxycarbonyl)nipecotate(148672-74-6)

Safety Data

• Hazardous Substances Data: 148672-74-6(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 71962-74-8 Ethyl nipecotate 
• 4842-86-8 ethyl piperidine-3-carboxylate hydrochloride 

Downstream Products

• 1624302-00-6 1-tert-butyl 3-ethyl 3-methyl piperidine-1,3,3-tricarboxylate 
• 934270-61-8 3-benzyl-5-[(tert-butoxycarbonyl)piperidin-3-yl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol 
• 884512-51-0 tert-butyl 3-(2,2,2-trifluoroacetyl)piperidine-1-carboxylate 
• 189320-44-3 1-t-butyl 3-ethyl 3-(2-nitrobenzyl)-1,3-piperidinedicarboxylate 
• 859154-32-8 3-hydrazinocarbonyl-piperidine-1-carboxylic acid tert-butyl ester 
• 435309-95-8 N-(BOC)-(D,L)-3-(4'-bromophenyl)sulfonyl-nipecotic acid, ethyl ester 
• 278789-43-8 ethyl N-t-butyloxycarbonyl-3-methylpiperidine-3-carboxylate 
• 1041846-33-6 3-(2-bromo-phenylcarbamoyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 923009-49-8 1-(tert-butyl) 3-ethyl 3-(cyanomethyl)piperidine-1,3-dicarboxylate 
• 923009-79-4 1-tert-butyl 3-ethyl 3-[2-(benzyloxy)-2-oxoethyl]piperidine-1,3-dicarboxylate 
• 923009-67-0 tert-butyl 3,3-dimethyl-1-oxo-2-oxa-7-azaspiro[4.5]decane-7-carboxylate 
• 1186019-70-4 C₂₁H₃₆N₄O₄ 
• 1186019-61-3 1-tert-butyl 3-ethyl 3-({2-[(benzyloxy)carbonyl]hydrazino}carbonyl)piperidine-1,3-dicarboxylate 
• 1186019-60-2 3-benzyl 1-tert-butyl 3-ethyl piperidine-1,3,3-tricarboxylate 

Relevant articles and documents

Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors

Structure-based methods were used to design β-sulfone 3,3-piperidine hydroxamates as TACE inhibitors with the aim of improving selectivity for TACE versus MMP-13. Several compounds in this series were synthesized and evaluated in enzymatic and cell-based

PYRAZOLOPYRIDAZINE DERIVATIVES, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE SAME

The present invention is a pyrazolopyridazine derivative. A pharmaceutical composition for preventing or treating cancer contains the pyrazolopyridazin derivative compound Hsp90 according to the present invention as an active ingredient, which can be used as Hsp90 a pharmaceutical composition for preventing or treating Hsp90-related diseases such as melanoma, brain tumor, breast cancer, lung cancer and the like. (by machine translation)

PHARMACEUTICAL COMPOUNDS

This invention relates to compounds that are agonists of the muscarinic M1 receptor or M1 and M4 receptors and which are useful in the treatment of muscarinic M1 or M1/M4 receptor mediated